Randomized placebo-controlled EPPIC trials of AST-120 in CKD

Journal of the American Society of Nephrology

Volumn 26, Issue 7, 2015, Pages 1732-1746

  Schulman, Gerald ^a   Berl, Tomas ^b   Beck, Gerald J ^c   Remuzzi, Giuseppe ^d   Ritz, Eberhard ^e   Arita, Kiyoshi ^f   Kato, Akira ^g   Shimizu, Miho ^f  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^g KUREHA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AST 120; CREATININE; PLACEBO; CARBON; OXIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLATULENCE; GASTRITIS; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NUTRITIONAL DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SKIN DISEASE; VOMITING; AGED; BLOOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MORTALITY; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; CARBON; CONFIDENCE INTERVALS; CREATININE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OXIDES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84934757695     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014010042     Document Type: Article

References (32)

1. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
3. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS; Chronic Kidney Disease Prognosis Consortium: Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 307: 1941-1951, 2012
4. National Institutes of Health: USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, 2012. Available at http://www.usrds.org/atlas12.aspx. Accessed April 17, 2014
5. James MT, Hemmelgarn BR, Tonelli M: Early recognition and prevention of chronic kidney disease. Lancet 375: 1296-1309, 2010
6. National Kidney Foundation: KDOQI clinical practice guideline for diabetes and CKD: 2012 update. AmJ Kidney Dis 60: 850-886, 2012
7. Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43[Suppl 1]: S1-S290, 2004
8. Andrassy KM; National Kidney Foundation: Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'. Kidney Int 84: 622-623, 2013
9. Levey AS, Coresh J: Chronic kidney disease. Lancet 379: 165-180, 2012
10. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285: 2719-2728, 2001
11. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K,Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (theONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008
12. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev (3): CD007004, 2009
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
15. Vanholder R, De Smet R, GlorieuxG, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943, 2003
16. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 1551-1558, 2009
17. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uraemic Toxin Work Group (EUTox): Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25: 1183-1191, 2010
18. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P: p-Cresol and cardiovascular risk inmild-to-moderate kidney disease. Clin J AmSoc Nephrol 5: 1182-1189, 2010
19. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS: p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 26: 938-947, 2011
20. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H: Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ Res 111: 1470-1483, 2012
21. Akizawa T, Koide K, Koshikawa S: Effects of Kremezin on patients with chronic renal failure-results of a nation-wide clinical study. Kidney Dial 45: 373-388, 1998 [Japanese]
22. Hatakeyama S, Yamamoto H,Okamoto A, Imanishi K, Tokui N,Okamoto T, Suzuki Y, Sugiyama N, Imai A, Kudo S, Yoneyama T, Hashimoto Y, Koie T, Kaminura N, Saitoh H, Funyu T,Ohyama C: Effect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with chronic kidney disease. Int J Nephrol 2012: 376128, 2012
23. Konishi K,Nakano S, Tsuda S,Nakagawa A, Kigoshi T, Koya D: AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 81: 310-315, 2008
24. Yorioka N, Kiribayashi K, Naito T, Ogata S, Yokoyama Y, Kyuden Y, Ogawa T, Wada K, Hayashi K, Hirabayashi A: An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease. J Nephrol 21: 213-220, 2008
25. Niwa T, Yazawa T, Ise M, Sugano M, Kodama T, Uehara Y, Maeda K: Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. Nephron 57: 84-88, 1991
26. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Suzuki T, Ueda Y, Yamagishi S: Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 60: 260-264, 2011
27. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N: A multicenter, randomized, double-blind, placebo-controlled, doseranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 47: 565-577, 2006
28. Shoji T, Wada A, Inoue K, Hayashi D, Tomida K, Furumatsu Y, Kaneko T, Okada N, Fukuhara Y, Imai E, Tsubakihara Y: Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 105: c99-c107, 2007
29. KeaneWF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, MitchWE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63: 1499-1507, 2003
30. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-115, 1975
31. Marier JF, Lee J, Kambhampati SR, Galitz L, Vargas R, Moberly J, SalazarDE: Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease. Am J Nephrol 26: 136-141, 2006
32. Hays RD, Kallich JD, Mapes DL, Coons SJ, CarterWB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 3: 329-338, 1994